Abstract
883P - Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have